Get the Stockscreener App
113.82
77.55%
49.71
Arcellx Inc stock is traded at $113.82, with a volume of 17.87M.
It is up +77.55% in the last 24 hours and up +68.14% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$64.11
Open:
$114.14
24h Volume:
17.87M
Relative Volume:
14.27
Market Cap:
$6.58B
Revenue:
$76.81M
Net Income/Loss:
$-162.42M
P/E Ratio:
-38.07
EPS:
-2.99
Net Cash Flow:
$-122.49M
1W Performance:
+66.18%
1M Performance:
+68.14%
6M Performance:
+59.69%
1Y Performance:
+78.56%
1-Day Range:
$113.80
$114.26
1-Week Range:
$63.15
$114.26
52-Week Range:
$47.86
$114.26
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
113.83 | 3.71B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.34 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.36 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.86 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.61 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
365.16 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-22-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-16-25 | Initiated | Stifel | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
Gilead buys Arcellx before it’s over the finish line | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion - marketscreener.com
Gilead to buy Arcellx in $7.8bn deal to advance multiple myeloma treatment - BioXconomy
Gilead Sciences Enters $7.8 Billion Definitive Agreement to Acquire Arcellx - Pharmaceutical Executive
Shareholder Alert: The Ademi Firm investigates whether Arcellx Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Arcellx Surges as Gilead’s $7.8B Offer Locks In a 68% Premium - Investing.com
Novo Nordisk, Lilly, Arcellx, American Airlines, Strategy, Domino’s, and More Movers - Barron's
Why Did Arcellx (ACLX) Stock Surge 70%? $7.8B Buyout Deal - Tokenist
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Arcellx Stock Surges on Promising Cancer Treatment News - StocksToTrade
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - WTVB
Why is Arcellx stock up 80% today? Gilead’s $7.8B answer - Invezz
Gilead Sciences To Acquire Arcellx In $7.8 Billion Deal To Strengthen Cell Therapy Portfolio - Pulse 2.0
Arcellx surges after Gilead agrees to acquire the CAR-T biotech in a deal worth up to $7.8B - Quiver Quantitative
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy - BioPharma Dive
Novo’s next-gen obesity drug stumbles in Lilly comparison study - statnews.com
Gilead to buy Arcellx for $7.8B, gaining full control of anito-cel - FirstWord Pharma
Spider silk strong enough to tow a car is headed for mass production in Vietnam - Stock Titan
Gilead to Buy US Biotech Arcellx for Up to $7.8 Billion - Bloomberg.com
Sector Update: Health Care Stocks Mixed Premarket Monday - marketscreener.com
Morning Movers: Arcellx skyrockets following pact to be acquired - TipRanks
Gilead Sciences Acquires Arcellx, for $7.8 Billion - FinSMEs
Gilead Sciences to snap up Arcellx in near $8bn deal - Sharecast.com
Why Arcellx Stock Is Dropping Despite Buyout Deal - TipRanks
Truist cuts Arcellx stock rating on Gilead acquisition deal By Investing.com - Investing.com India
Gilead Sciences Acquires Arcellx - Contract Pharma
This Biotech Stock Is Surging 78%. Gilead Sciences Has Agreed to Buy It. - Barron's
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition - BioSpace
Gilead Snaps Up Arcellx in $7.8B Cancer Drug Deal - RagingBull
Arcellx stock soars 78% as Gilead agrees to $7.8B acquisition - Investing.com India
US Gilead Sciences acquires cancer drug developer Arcellx for $7.8B - Anadolu Ajansı
Gilead buys cell therapy partner Arcellx for up to $7.8bn - pharmaphorum
ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders - The National Law Review
Gilead Sciences (GILD) Announces Strategic Merger with Arcellx - GuruFocus
Gilead to buy US biotech Arcellx for up to US$7.8 billion - The Business Times
Gilead to acquire Arcellx in deal worth $7.8bn - PMLiVE
Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug - Benzinga
M&A News: Arcellx Stock (ACLX) Booms 70% after Gilead Buys Cancer-Fighting Biotech for $7.8B - TipRanks
US Premarket Movers: Arcellx, Domino’s, MoonLake, Vanda, Veris - Bloomberg
This Biotech Stock Is Surging 78%. Gilead Sciences Agrees to Buy It. - Barron's
Gilead punts $7.8 billion on acquisition of Arcellx - The Pharma Letter
Biotech M&A heats up with Gilead-Arcellx deal - Axios
Gilead to acquire biotech Arcellx, valued at $7.8 billion - The Weekly Journal
Gilead Acquires Anito-Cel Partner Arcellx Ahead Of US FDA Decision - Citeline News & Insights
Gilead to acquire Arcellx for $7.8 billion in cash deal - Investing.com
Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino's Pizza and more - CNBC
Gilead inks $8B Arcellx buyout to steer CAR-T into J&J showdown - Fierce Biotech
Gilead Sciences to Acquire Arcellx in Major Cell-Therapy Deal - TipRanks
M&A snapshot: Gilead acquires Arcellx for $7.8B - MSN
Gilead shows belief in its partner’s cancer treatment with $7.8 billion buyout - MarketWatch
Gilead to buy US biotech Arcellx for up to US$7.8 bil - The Edge Malaysia
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcellx Inc Stock (ACLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Jan 03 '26 |
Option Exercise |
0.00 |
15,340 |
0 |
44,302 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Feb 19 '26 |
Sale |
68.29 |
8,384 |
572,568 |
45,157 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Jan 02 '26 |
Option Exercise |
0.00 |
20,496 |
0 |
28,962 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Feb 17 '26 |
Sale |
69.51 |
11,291 |
784,783 |
53,541 |
1.14%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):